Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

DALINGO 82,5 MG COMPRIMIDOS DE LIBERACIÓN PROLONGADA - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/DALINGO 82,5 MG COMPRIMIDOS DE LIBERACIÓN PROLONGADA

Approved

STANDARD

DALINGO 82,5 MG COMPRIMIDOS DE LIBERACIÓN PROLONGADA

Laboratorios Gebro Pharma S.A.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Feb 13, 2024
Approval ID: e021626d7b13dedb
Company: Laboratorios Gebro Pharma S.A.
Type: Standard

Approval Details

Approval Id: e021626d7b13dedb
Drug Cima Aemps Name: DALINGO 82,5 MG COMPRIMIDOS DE LIBERACIÓN PROLONGADA
Register Number: 89266
Holder Company Name: Laboratorios Gebro Pharma S.A.
Marketing Company Name: Laboratorios Gebro Pharma S.A.
Authorization Date: 2024-02-13
Dosage Form: COMPRIMIDO DE LIBERACIÓN PROLONGADA
Dose: 82,5 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Laboratorios Gebro Pharma S.A.

Active Ingredients

PREGABALINA

82,5 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Feb 13, 2024

Approval ID

e021626d7b13dedb

Type

Standard

Back to CIMA-AEMPS Approvals